Medical Care CPI: The Drug vs Device Divide

Medical care represents 8.3% of the Consumer Price Index—modest compared to housing's 44%, but with outsized importance for a $4.5 trillion healthcare sector. Unlike other CPI components that move in predictable cycles, medical inflation follows its own rhythm: policy changes, patent cliffs, pandemic disruptions, and insurer negotiations create volatility that splits the healthcare sector into winners and losers.

The data reveals a counterintuitive pattern. When medical inflation is low—below 1.5% annually—growth stocks like Eli Lilly (+16.79%/quarter) dominate. When inflation runs hot—above 5%—distributors like Cardinal Health surge (+26.51%) while medical device makers collapse (-10% to -15%). The middle ground favors diversified names and healthcare services companies. Understanding these regimes is essential for anyone positioned in the sector.

I. Understanding Medical Care CPI

Medical Care CPI tracks what consumers pay for healthcare goods and services. It has two major subcomponents: Medical Care Commodities (prescription drugs, medical equipment) and Medical Care Services (physician visits, hospital stays, health insurance). These components behave differently, creating divergent opportunities within the healthcare sector.

The left chart shows a striking pattern: drug prices went deflationary in 2019 and 2021 (-0.10% and -1.52% respectively) while medical services kept climbing (+3.53% and +1.86%). This decoupling happens when generic competition, patent expirations, or government price negotiations overwhelm branded drug price increases. In 2023, the pattern reversed: drug prices jumped +3.91% while services fell -0.32%.

For investors, this divergence is crucial. Pharma companies benefit from drug inflation (pricing power), but innovative drug makers like Eli Lilly can thrive even in drug deflation if their pipeline is strong enough to gain market share. Medical service providers (hospitals, insurers) respond to the services component. The regime classification below captures the aggregate effect.

II. Regime Performance Analysis

We classify medical inflation into four regimes based on quarterly YoY readings: Low (<1.5%), Normal (1.5-3%), Elevated (3-5%), and High (>5%). Over 64 quarters, Normal accounts for 31 quarters (48%), Elevated for 27 (42%), Low for 5 (8%), and High for just 1 quarter (2%).

The table reveals three distinct patterns:

1. Low-inflation winners: LLY (+16.79%) and ISRG (+13.29%) crushed in the Low regime. These are growth-oriented names with innovative pipelines. When medical inflation falls below 1.5%, pricing power matters less than innovation—and these companies have it. Note LLY's perfect 100% win rate in Low quarters.

2. Elevated-inflation winners: REGN (+7.44%), RMD (+6.10%), and ABBV (+5.99%) excel when medical prices run hot. Regeneron benefits from Eylea pricing; ResMed from device pricing power in sleep apnea; AbbVie from Humira's dominance (now biosimilar competition, but historically strong).

3. Low-inflation losers: BMY (-6.24%) and PFE (-2.84%) struggle when inflation is low. Both are mature pharma companies with less pipeline optionality. When drugs deflate, they lack the growth offset.

III. Investment Framework

The data supports a regime-based approach to healthcare allocation. The key is matching company characteristics to the inflation environment.

Low Medical Inflation (<1.5%): Innovation Wins

When medical prices fall, the market rewards growth over pricing power. Innovative drug makers with strong pipelines outperform because their value comes from new products, not existing price increases. Surgical robotics (ISRG) benefits from procedure volume growth independent of pricing. The trade: overweight LLY, ISRG, ZTS, DHR.

Normal Medical Inflation (1.5-3%): Diversified Quality

This is the most common regime (48% of quarters). Returns are more compressed, and winners are spread across subsectors. Healthcare services (HCA, CI), biotech (VRTX), and devices (EW, BSX) all perform well. The play is quality across the sector.

Elevated Medical Inflation (3-5%): Pricing Power

This is our current regime. When medical prices rise 3-5% annually, companies with pricing power excel. REGN leads with Eylea; RMD with sleep devices; ABBV with immunology drugs. JNJ offers the highest win rate (74%) for stability. Avoid low-margin names like CVS.

High Medical Inflation (>5%): Defensive Rotation

If medical inflation spikes above 5%, the playbook changes dramatically. Distributors (CAH, MCK) benefit from pass-through pricing. Hospitals (HCA) gain from service price increases. But device makers and diagnostics companies get crushed as procedure volumes fall and cost pressures mount. The trade: overweight CAH, MCK, HCA; underweight ISRG, EW, ABT, MDT.

IV. Conclusion

Medical Care CPI creates a regime-based opportunity within healthcare. The current Elevated environment (3.15%) favors pricing power names like REGN, RMD, and ABBV, while the risk of a spike above 5% argues for maintaining some distributor exposure (CAH, MCK). Avoid device makers with high input cost sensitivity (MDT, BDX) unless inflation retreats.

The 2023 medical deflation was a preview of where the sector could go if drug price negotiations expand. In that scenario, rotate heavily into growth stories (LLY, ISRG) and away from mature pharma (PFE, BMY). Monitor drug CPI vs services CPI divergence—it's an early warning indicator.